Skip to content Skip to footer


Next scientific publication is online!
Our new scientific publication is now published in Plos One. In this publication we present an extensive preclinical evaluation of…
PROVIREX took third place at the 21st Göttingen Innovation Award!
We took third place in the Göttingen Innovation Award 2023 in the category "Companies with up to 20 employees"! Many…
Official laying of the foundation stone for the new tecHHub building!
In rainy and stormy weather, the official ceremony for the start of the construction of the new tecHHub building for…
PROVIREX has been nominated for the Hamburg 2040 Award!
With this award, the Hamburg Chamber of Commerce (Handelskammer) recognises companies, institutions or individuals who are actively shaping the future…
The new PROVIREX laboratories have been officially approved and are now ready for operation
Since August 2022, we have been setting up two completely new laboratories and registering them with the authorities to continue…
PROVIREX receives funding from IFB Hamburg to develop novel HIV therapy
PROVIREX Genome Editing Therapies GmbH Hamburg and the University Medical Centre Hamburg-Eppendorf will receive R&D funding from the Hamburg Investment…
New lead investor joins PROVIREX
Bioventure joins PROVIREX as a lead investor! IFB Innovationstarter GmbH also increases its investment as a co-investor. These investments will…
Starting signal to set up a therapy hub at Science City Hamburg Bahrenfeld
At an exclusive press event on October 27, 2022, at Factory Hammerbrooklyn, the official go-ahead was given to establish a…
PROVIREX moves into Start-Up Labs Bahrenfeld
PROVIREX started renting laboratories and office space in the Start-Up Labs Bahrenfeld on the DESY campus. The newly established workspace…
Ascenion GmbH and Innovationsstarter Fonds Hamburg GmbH acquire shares in PROVIREX
Researchers from Hamburg plan to use a new gene and cell method to transform the treatment of HIV patients in…
PROVIREX’s proprietary Brec1 technology enters clinical testing as a first-in-human phase
PROVIREX’s proprietary Brec1 technology enters clinical testing as a first-in-human phase Ib/IIa clinical trial (HIVcure) aiming to remove HIV-1 from infected…
Founding of the company PROVIREX Genome Editing Therapies GmbH
Founding of the company PROVIREX Genome Editing Therapies GmbH

Scientific Publications

  1. Beschorner N, Künzle P, Voges M, Hauber I, Indenbirken D, Nakel J, Sanamjeet Virdi, Peter Bradtke, Niels Christian Lory, Michael Rothe, Maciej Paszkowski-Rogacz, Frank Buchholz, Adam Grundhoff, Axel Schambach, Christian Thirion, Hans-Willi Mittruecker, Julian Schulze zur Wiesch, Joachim Hauber, Jan Chemnitz (2024). Preclinical toxicity analyses of lentiviral vectors expressing the HIV-1 LTR-specific designer-recombinase Brec1. PLoS ONE 19(3): e0298542.
  2. Rojo-Romanos, T., Karpinski, J., Millen, S., Beschorner, N., Simon, F., Paszkowski-Rogacz, M., Lansing, F., Schneider, P.M., Sonntag, J., Hauber, J., Thoma-Kress, A., and Buchholz, F. (2023). Precise Excision of HTLV-1 Provirus with a Designer-Recombinase. Molecular Therapy 31, 2266-2286.
  3. Karpinski, J., Hauber, I., Chemnitz, J., Schäfer, C., Paszkowski-Rogacz, M., Chakraborty, D., Beschorner, N., Hofmann-Sieber, H., Lange, U.C., Grundhoff, A., Hackmann, K., Schrock, E., Abi-Ghanem, J., Pisabarro, M.T., Surendranath, V., Schambach, A., Lindner, C., van Lunzen, J., Hauber, J., and Buchholz, F. (2016).  Directed Evolution of a Recombinase that Excises the Provirus of Most HIV-1 Primary Isolates with High Specificity. Nature Biotechnology 34, 401-409.
  4. Meinke, G., Bohm, A., Hauber, J., Pisabarro, M.T., and Buchholz, F. (2016). Cre Recombinase and Other Tyrosine Recombinases. Chemical Reviews 116, 12785-12820.
  5. Abi-Ghanem, J., Chusainow, J., Karimova, M., Spiegel, C., Hofmann-Sieber, H., Hauber, J., Buchholz, F., and Pisabarro, M.T. (2013). Engineering of a Target Site-Specific Recombinase by a Combined Evolution- and Structure-Guided Approach. Nucleic Acids Research 41, 2394-2403.
  6. Buchholz, F., and Hauber, J. (2016). Antiviral Therapy of Persistent Viral Infection Using Genome Editing. Current Opinion in VIROLOGY 20, 85-91.
  7. Hauber, I., Hofmann-Sieber, H., Chemnitz, J., Dubrau, D., Chusainow, J., Stucka, R., Hartjen, P., Schambach, A., Ziegler, P., Hackmann, K., Schröck, E., Schumacher, U., Lindner, C., Grundhoff, A., Baum, C., Manz, M.G., Buchholz, F., and Hauber, J. (2013). Highly Significant Antiviral Activity of HIV-1 LTR-Specific Tre-Recombinase in Humanized Mice. PLOS Pathogens 9, e1003587.
  8. Buchholz, F., and Hauber, J. (2013). Engineered DNA Modifying Enzymes: Components of a Future Strategy to Cure HIV/AIDS. Antiviral Research 97, 211-217.
  9. Mariyanna, L., Priyardarshini, P., Hofmann-Sieber, H., Krepstakies, M., Walz, N., Grundhoff, A., Buchholz, F., Hildt, E., and Hauber, J. (2012). Excision of HIV-1 Proviral DNA by Recombinant Cell Permeable Tre-Recombinase. PLOS ONE 7, e31576.
  10. Buchholz, F., and Hauber, J. (2011). In Vitro Evolution and Analysis of HIV-1 LTR-Specific Recombinases. Methods 53, 102-109.
  11. Sarkar, I., Hauber, I., Hauber, J., and Buchholz, F. (2007). HIV-1 Proviral DNA Excision Using an Evolved Recombinase. Science 316, 1912-1915.

Genome Editing Therapies GmbH

Luruper Hauptstraße 1
22547 Hamburg


Copyright © PROVIREX Genome Editing Therapies GmbH 2023